Astria Therapeutics Inc., a biopharmaceutical company focused on developing therapies for allergic and immunologic diseases, will present at the 14th C1 Inhibitor Deficiency and Angioedema Workshop in Budapest, Hungary, on May 31, 2025. Dr. Marc A. Riedl will present safety and efficacy data from the Phase 1a and Phase 1b/2 trials of navenibart in a presentation titled, "Navenibart for Hereditary Angioedema $(HAE)$: Analysis of Safety, Pharmacokinetic, and Pharmacodynamic Data From Phase 1a and Phase 1b/2 ALPHA-STAR Trial."
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.